Biotech firm advances skin cancer treatment program

Tampa-based Morphogenesis Inc.’s vaccine will be tested on humans in a clinical trial.

  • By Business Observer Staff
  • | 1:47 p.m. August 27, 2018
Investor Kiran Patel speaks at an event held to celebrate Morphogenesis Inc.'s successful application to conduct human clinical trials of its skin cancer vaccine. Courtesy photo.
Investor Kiran Patel speaks at an event held to celebrate Morphogenesis Inc.'s successful application to conduct human clinical trials of its skin cancer vaccine. Courtesy photo.
  • Tampa Bay-Lakeland
  • Share

TAMPA —  Morphogenesis Inc., a Tampa-based biotech company that raised $16 million in investment funding in May, will embark on the first human clinical study of its immunotherapeutic vaccine designed to treat melanoma.

 

Continue reading your article
with a Business Observer subscription.
What's included:
  • ✓ Unlimited digital access to BusinessObserverFL.com
  • ✓ E-Newspaper app, digital replica of print edition
  • ✓ Mailed print newspaper every Friday (optional)
  • ✓ Newsletter of daily business news
Subscribe

Already subscribed? Sign in.

Latest News

  • April 2, 2026
Sarasota Doctors Hospital names new COO
  • April 2, 2026
Babcock Ranch shopping center gets refinance
  • April 2, 2026
Report: Childhood poverty pockets remain in region amid Florida decline
  • April 2, 2026
Hillsborough to spend $70M on stormwater drainage improvements

Sponsored Content